Thomas W. Beetham - 02 Mar 2026 Form 4 Insider Report for Viridian Therapeutics, Inc.\DE (VRDN)

Reporting relationship: Chief Operating Officer
Issuer ticker: VRDN
Reported as of: 02 Mar 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 04 Mar 2026, 18:58:34 UTC
Prior SEC filing: 04 Mar 2025
Next SEC filing: 09 Mar 2026
Source filing: View source filing
Reporting owner signature: Jennifer Tousignant, Attorney-in-fact

Key filing fact

Thomas W. Beetham filed Form 4 for Viridian Therapeutics, Inc.\DE (VRDN) on 04 Mar 2026.

Key facts

This page summarizes Thomas W. Beetham's Form 4 filing for Viridian Therapeutics, Inc.\DE (VRDN).
5 reported transactions and 3 derivative rows are listed below.
Accepted by SEC: 04 Mar 2026, 18:58.

Change

Previous filing in this sequence was filed on 04 Mar 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001741382 Primary reporting owner

Beetham Thomas W.

Relationship: Chief Operating Officer
Address: C/O VIRIDIAN THERAPEUTICS, INC., 221 CRESCENT STREET, SUITE 103A, WALTHAM
Signature: Jennifer Tousignant, Attorney-in-fact
Signature date: 04 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

VRDN transaction

Common Stock

Options Exercise

Transaction value
Shares: +9,409
Change %: +134%
Price
Shares after: 16,409
Date: 03 Mar 2026
Ownership: Direct
Footnotes: F2, F5

VRDN transaction

Common Stock

Tax liability

Transaction value
Shares: -3,138
Change %: -19%
Price: $29.32^*
Shares after: 13,271
Date: 03 Mar 2026
Ownership: Direct
Footnotes: F5

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

VRDN transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +176,550
Change %
Price: $0.000000^*
Shares after: 176,550
Date: 02 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 176,550
Exercise price: $30.25
Footnotes: F1

VRDN transaction Derivative

Restricted Stock Units

Award

Transaction value
Shares: +35,300
Change %
Price: $0.000000^*
Shares after: 35,300
Date: 02 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 35,300
Exercise price
Footnotes: F2, F3

VRDN transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value
Shares: -9,409
Change %: -25%
Price: $0.000000^*
Shares after: 28,227
Date: 03 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 9,409
Exercise price
Footnotes: F2, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

The option vests and becomes exercisable in 48 equal monthly installments following the date of the grant, subject to the Reporting Person's continued service to Issuer through each vesting date. The date of the grant is March 2, 2026.

Footnote F2

Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of the Issuer.

Footnote F3

The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 2, 2026, subject to the Reporting Person's continued service to Issuer through each vesting date.

Footnote F4

The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 3, 2025, subject to the Reporting Person's continued service to Issuer through each vesting date.

Footnote F5

Includes 1,000 shares acquired under Viridian Therapeutics, Inc.'s 2016 Employee Stock Purchase Plan (the "ESPP") on March 17, 2025 in transactions that were exempt under Rule 16b-3(c).